BioSpace News Archive

Qualigen Therapeutics, Inc. announces that two abstracts featuring the Company’s pan-RAS inhibitor program will be included in the American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting Abstract Book.

Fractyl Health announced today that it will be presenting updates on its Revita ® and Rejuva ® programs at several upcoming medical congresses in May 2023.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the commercial launch of the Evo® sEEG electrode product line in the United States.

CollPlant Biotechnologies announced that it will report financial results for the first quarter of 2023 on May 24, 2023, before the market open.

AllerVie Clinical Research, an affiliate of AllerVie Health and a nationally recognized network of clinical research sites, announced the appointment of Dr. Weily Soong as its new chief research innovation officer.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced that the Company will report its financial results for the three months ended March 31, 2023, on Tuesday, May 9, 2023, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Elixir Medical, a developer of breakthrough cardiovascular technologies, announced that data from its BIOADAPTOR RCT randomized controlled trial, an international, multicenter, single-blind study enrolling 445 patients will be presented at the EuroPCR conference in Paris.

Acadia Pharmaceuticals Inc. announced that it will participate at the following upcoming investor conferences.

The Insight Partners published latest research report on “Biosafety Cabinet Market Size Report, Share, Growth, Trends & Forecasts to 2028 - COVID-19 Impact and Global Analysis By Products Handled, Category, Type, Application and End User”,

Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies for solid tumors, today announced the Company presented at the Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida April 14-19, 2023.